Growth Metrics

ImmunityBio (IBRX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $57.1 million.

  • ImmunityBio's Total Current Liabilities fell 627.62% to $57.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.1 million, marking a year-over-year decrease of 627.62%. This contributed to the annual value of $54.9 million for FY2024, which is 572.89% down from last year.
  • As of Q3 2025, ImmunityBio's Total Current Liabilities stood at $57.1 million, which was down 627.62% from $50.6 million recorded in Q2 2025.
  • ImmunityBio's 5-year Total Current Liabilities high stood at $613.5 million for Q2 2023, and its period low was $49.2 million during Q1 2025.
  • Over the past 5 years, ImmunityBio's median Total Current Liabilities value was $70.8 million (recorded in 2022), while the average stood at $191.2 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 46052.08% in 2021, then plummeted by 9048.42% in 2024.
  • Over the past 5 years, ImmunityBio's Total Current Liabilities (Quarter) stood at $369.0 million in 2021, then soared by 35.74% to $500.9 million in 2022, then crashed by 88.36% to $58.3 million in 2023, then decreased by 5.73% to $54.9 million in 2024, then grew by 3.99% to $57.1 million in 2025.
  • Its Total Current Liabilities was $57.1 million in Q3 2025, compared to $50.6 million in Q2 2025 and $49.2 million in Q1 2025.